TCRT
Alaunos Therapeutics Inc
Alaunos Therapeutics Inc historical holders
total: 3
Third Point Alaunos Therapeutics Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2015 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2015 Q3
Daniel Loeb has been an institutional investor in Alaunos Therapeutics Inc (TCRT) since 2015 Q2. According to 2026 Q1 report, Daniel Loeb doesn't hold any shares. The fund/company first acquired TCRT in 2015 Q2, initially purchasing about 1.95M shares. Since the initial investment, Third Point has made 1 more transaction in this position.
When did Daniel Loeb exit their TCRT position?
Daniel Loeb no longer holds Alaunos Therapeutics Inc (TCRT). They sold off their entire position in 2015 Q3, closing out an investment that began in 2015 Q2.
When did Daniel Loeb first invest in TCRT?
Daniel Loeb first invested in Alaunos Therapeutics Inc (TCRT) in 2015 Q2 at the reported quarter-end price of $12.00 per share, acquiring 1,950,000 shares in their initial purchase.
What is Daniel Loeb's average cost basis for TCRT?
Based on historical transaction data, Daniel Loeb's estimated cost basis for Alaunos Therapeutics Inc (TCRT) is approximately $12.00 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $12.00
- Weighted AVG sell price:
- $12.00
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.